Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 7.14
PACB's Cash to Debt is ranked higher than
67% of the 1270 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. PACB: 7.14 )
PACB' s 10-Year Cash to Debt Range
Min: 6.81   Max: No Debt
Current: 7.14

Equity to Asset 0.44
PACB's Equity to Asset is ranked higher than
61% of the 968 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PACB: 0.44 )
PACB' s 10-Year Equity to Asset Range
Min: -2.1   Max: 0.92
Current: 0.44

-2.1
0.92
F-Score: 5
Z-Score: -4.03
M-Score: -3.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -103.73
PACB's Operating margin (%) is ranked higher than
72% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. PACB: -103.73 )
PACB' s 10-Year Operating margin (%) Range
Min: -65237.04   Max: -275.16
Current: -103.73

-65237.04
-275.16
Net-margin (%) -109.19
PACB's Net-margin (%) is ranked higher than
71% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -78.17 vs. PACB: -109.19 )
PACB' s 10-Year Net-margin (%) Range
Min: -64965.19   Max: -281.37
Current: -109.19

-64965.19
-281.37
ROE (%) -106.13
PACB's ROE (%) is ranked higher than
59% of the 1154 Companies
in the Global Biotechnology industry.

( Industry Median: -34.19 vs. PACB: -106.13 )
PACB' s 10-Year ROE (%) Range
Min: -272.85   Max: -46.42
Current: -106.13

-272.85
-46.42
ROA (%) -50.76
PACB's ROA (%) is ranked higher than
64% of the 1274 Companies
in the Global Biotechnology industry.

( Industry Median: -27.54 vs. PACB: -50.76 )
PACB' s 10-Year ROA (%) Range
Min: -81.89   Max: -41.75
Current: -50.76

-81.89
-41.75
ROC (Joel Greenblatt) (%) -801.22
PACB's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 1243 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. PACB: -801.22 )
PACB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2466.26   Max: -529.13
Current: -801.22

-2466.26
-529.13
Revenue Growth (3Y)(%) 38.30
PACB's Revenue Growth (3Y)(%) is ranked higher than
95% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. PACB: 38.30 )
PACB' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 38.3
Current: 38.3

0
38.3
EBITDA Growth (3Y)(%) -56.40
PACB's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -4.50 vs. PACB: -56.40 )
PACB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -56.4
Current: -56.4

EPS Growth (3Y)(%) -55.30
PACB's EPS Growth (3Y)(%) is ranked higher than
54% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. PACB: -55.30 )
PACB' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -55.3
Current: -55.3

» PACB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PACB Guru Trades in Q1 2014

Jim Simons 105,766 sh (New)
Steven Cohen 10,300 sh (New)
Lee Ainslie 6,459,784 sh (unchged)
Murray Stahl 12,000 sh (unchged)
» More
Q2 2014

PACB Guru Trades in Q2 2014

Murray Stahl 12,000 sh (unchged)
Lee Ainslie 6,459,784 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

PACB Guru Trades in Q3 2014

Murray Stahl 12,000 sh (unchged)
Lee Ainslie 6,459,784 sh (unchged)
» More
Q4 2014

PACB Guru Trades in Q4 2014

Jim Simons 137,972 sh (New)
Murray Stahl 12,000 sh (unchged)
Lee Ainslie 6,459,784 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PACB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2013-09-30 Add 64.63%0.17%$2.5 - $5.98 $ 6.7596%5814719
Jean-Marie Eveillard 2012-09-30 Sold Out 0.0013%$1.7 - $2.32 $ 6.75243%0
John Griffin 2012-06-30 Sold Out 0.05%$1.83 - $3.7 $ 6.75172%0
Jean-Marie Eveillard 2012-03-31 New Buy$2.94 - $5.04 $ 6.7582%150000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.82
PACB's P/B is ranked higher than
64% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 6.64 vs. PACB: 8.82 )
PACB' s 10-Year P/B Range
Min: 0.52   Max: 10.72
Current: 8.82

0.52
10.72
P/S 8.93
PACB's P/S is ranked higher than
83% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 30.34 vs. PACB: 8.93 )
PACB' s 10-Year P/S Range
Min: 2   Max: 28.19
Current: 8.93

2
28.19
EV-to-EBIT -6.51
PACB's EV-to-EBIT is ranked higher than
74% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PACB: -6.51 )
PACB' s 10-Year EV-to-EBIT Range
Min: -7.8   Max: 0.5
Current: -6.51

-7.8
0.5
Current Ratio 2.11
PACB's Current Ratio is ranked higher than
61% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. PACB: 2.11 )
PACB' s 10-Year Current Ratio Range
Min: 2.11   Max: 14.06
Current: 2.11

2.11
14.06
Quick Ratio 1.90
PACB's Quick Ratio is ranked higher than
63% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. PACB: 1.90 )
PACB' s 10-Year Quick Ratio Range
Min: 1.9   Max: 13.74
Current: 1.9

1.9
13.74
Days Inventory 99.17
PACB's Days Inventory is ranked higher than
90% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PACB: 99.17 )
PACB' s 10-Year Days Inventory Range
Min: 164.72   Max: 196.1
Current: 99.17

164.72
196.1
Days Sales Outstanding 20.52
PACB's Days Sales Outstanding is ranked higher than
95% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 116.17 vs. PACB: 20.52 )
PACB' s 10-Year Days Sales Outstanding Range
Min: 28.21   Max: 74.35
Current: 20.52

28.21
74.35

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.79
PACB's Price/Net Cash is ranked higher than
76% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 55.07 vs. PACB: 15.79 )
PACB' s 10-Year Price/Net Cash Range
Min: 1.02   Max: 12.12
Current: 15.79

1.02
12.12
Price/Net Current Asset Value 12.57
PACB's Price/Net Current Asset Value is ranked higher than
77% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 35.37 vs. PACB: 12.57 )
PACB' s 10-Year Price/Net Current Asset Value Range
Min: 0.95   Max: 9.97
Current: 12.57

0.95
9.97
Price/Tangible Book 8.82
PACB's Price/Tangible Book is ranked higher than
72% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. PACB: 8.82 )
PACB' s 10-Year Price/Tangible Book Range
Min: 0.8   Max: 7.36
Current: 8.82

0.8
7.36
Price/Median PS Value 1.13
PACB's Price/Median PS Value is ranked higher than
84% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. PACB: 1.13 )
PACB' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 3.45
Current: 1.13

0.38
3.45
Earnings Yield (Greenblatt) -15.40
PACB's Earnings Yield (Greenblatt) is ranked higher than
58% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. PACB: -15.40 )
PACB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 188.2   Max: 26942.4
Current: -15.4

188.2
26942.4

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:P09.Germany,
Pacific Biosciences of California, Inc., was incorporated in the State of Delaware in 2000. The Company develops, manufactures and markets an integrated platform for high resolution genetic analysis. It has developed a technology to study the synthesis, composition, structure, and regulation of DNA. Combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, it created a technology platform using its proprietary single molecule, real-time, or SMRT, technology. Its SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events as they occur. The ability to observe single molecule events in real time provides the scientific community with an advanced tool for investigating basic biochemical processes such as DNA synthesis. Its SMRT technology has the potential to advance scientific understanding by providing a window into biological processes that has not previously been open. It has commercialized the PacBioRS II High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, its products enable scientists to increase their understanding of biological systems through targeted sequencing and insight into genetic variations. The Company's products include the SMRT Cell, Phospholinked nucleotides, the PacBio RS. Its competitors include Illumina Inc. and Thermo Fisher Scientific Inc. The names "Pacific Biosciences," "PacBio," "SMRT," "SMRTbell" and its logo are the trademarks of the Company. It is subject to federal, state, local and foreign laws, regulations and permits relating to environmental, health and safety matters.
» More Articles for PACB

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: CLR, CLMS, OPK, PACB, GAIN Dec 16 2013 
Weekly CEO Buys Highlight: OPK, PACB, CUBI, ARCP, RLYP Nov 25 2013 
Weekly CEO Buys Highlight: PHII, TUES, PACB, IPHI, WMC Dec 09 2012 
Weekly CEO Buys Highlight: PACB, AKS, EPIQ, GGS, TPGI Dec 02 2012 
Weekly CEO Buys Highlight: FFIN, STEC, MPO, PACB, TPGI Nov 25 2012 
Weekly CEO Buys Highlight: SUNS, PACB, GM, NPO, DGX Aug 11 2012 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Feb 26 2015
10X Genomics Unwraps Its 'Toaster Oven' For Better DNA Sequencing Feb 25 2015
Five Things To Watch For At The Big Genomics Event Feb 24 2015
What 23andMe's FDA Approval Means For The Future Of Genomics Feb 20 2015
Pacific Biosciences Reports Fourth Quarter 2014 Financial Results Feb 11 2015
Pacific Biosciences Posts Q4 Loss as Expected, Shares Fall - Analyst Blog Feb 04 2015
Pacific Biosciences reports 4Q loss Feb 03 2015
Pacific Biosciences reports 4Q loss Feb 03 2015
Pacific Biosciences of California Inc Earnings Call scheduled for 4:30 pm ET today Feb 03 2015
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K, Entry into a Material Definitive... Feb 03 2015
Pacific Biosciences Reports Fourth Quarter 2014 Financial Results Feb 03 2015
Q4 2014 Pacific Biosciences of California Inc Earnings Release - After Market Close Feb 03 2015
Will Pacific Biosciences (PACB) Surprise on Earnings in Q4? - Analyst Blog Feb 02 2015
Pacific Biosciences of California, Inc. Fourth Quarter and Year End 2014 Financial Results Call Jan 12 2015
Stealthy 10X Genomics Raises $55.5M To Beef Up DNA Sequencing Jan 12 2015
Pacific Biosciences of California, Inc. Fourth Quarter and Year End 2014 Financial Results Call Jan 09 2015
Pacific Biosciences Customers Present Work on Complex De Novo Genomes and Genome Annotation at the... Jan 05 2015
Pacific Biosciences Appoints Kathy Ordonez to Board of Directors Dec 18 2014
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K, Change in Directors or Principal... Dec 18 2014
Pacific Biosciences Appoints Kathy Ordonez to Board of Directors Dec 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK